Unraveling the therapeutic potential of the Hedgehog pathway in cancer | Zendy

Dereck D. Amakye | Zendy; Zainab Jagani | Zendy; Marion Dorsch | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Unraveling the therapeutic potential of the Hedgehog pathway in cancer

Author(s) -

Dereck D. Amakye,

Zainab Jagani,

Marion Dorsch

Publication year - 2013

Publication title -

nature medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.536

H-Index - 547

eISSN - 1546-170X

pISSN - 1078-8956

DOI - 10.1038/nm.3389

Subject(s) - smoothened , hedgehog signaling pathway , hedgehog , vismodegib , cancer research , carcinogenesis , basal cell carcinoma , medulloblastoma , cancer , ptch1 , medicine , biology , bioinformatics , signal transduction , basal cell , microbiology and biotechnology

Major progress has been made in recent years in the development of Hedgehog (Hh) pathway inhibitors for the treatment of patients with cancer. Promising clinical trial results have been obtained in cancers that harbor activating mutations of the Hh pathway, such as basal cell carcinoma and medulloblastoma. However, for many cancers, in which Hh ligand overexpression is thought to drive tumor growth, results have been disappointing. Here we review the preclinical data that continue to shape our understanding of the Hh pathway in tumorigenesis and the emerging clinical experience with smoothened inhibitors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research